Compare Jumia Technologies AG - ADR (JMIA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Spyre Therapeutics Inc. Common Stock — how do they compare? Jumia Technologies AG - ADR trades at $5.72 (market cap $789.73M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 9.5× Jumia Technologies AG - ADR's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 29 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| JMIA | SYRE | |
|---|---|---|
Market Cap | $789.73M | $7.52B |
Volume | 1,367,204 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $108.92 |
52-Week Low | $5.69 | $22.18 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $755.37M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $5.79, down 5.24% on the day, amid a bearish technical outlook with all moving averages signaling sell. Fundamentally, the company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights a $50 million capital raise and progress toward EBITDA breakeven by year-end 2026, per company reports from August 2026.
The outlook is mixed: analyst consensus is bullish with a $12 price target, but high execution risks persist given persistent losses and negative ROE. Investors face volatility from operational cash burn and competitive pressures in African e-commerce, though cost controls and growth initiatives offer potential upside if profitability targets are met.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
